Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
about
Aromatase Inhibitors for the adjuvant treatment of breast cancer in postmenopausal womenAdjuvant systemic therapy in older women with breast cancerRole of bone-anabolic agents in the treatment of breast cancer bone metastasesDenosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patientsUnderstanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonanceBisphosphonates in breast cancerA systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancerNoninvasive imaging of cardiovascular injury related to the treatment of cancerAdjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Adjuvant treatment for older women with invasive breast cancerThe effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeletonCancer drug related cardiotoxicity during breast cancer treatment.Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data.Ischemic Heart Disease: Special Considerations in Cardio-Oncology.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Treatment outcomes for male breast cancer: a single-centre retrospective case-control study.Comorbidities and cardiovascular disease risk in older breast cancer survivorsConsiderations for payers in managing hormone receptor-positive advanced breast cancer.Cardiovascular Late Effects and Exercise Treatment in Breast Cancer: Current Evidence and Future DirectionsCancer, physical activity, and exerciseEffects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapyManagement options of breast cancer related osteoporosis.Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomicsA randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.Breast cancer survivorship issues.A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients.Multicriteria decision analysis in oncology.Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.Association of tamoxifen use and increased diabetes among Asian women diagnosed with breast cancerA prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.Molecular Heterogeneity in Primary Breast Carcinomas and Axillary Lymph Node Metastases Assessed by Genomic Fingerprinting Analysis.The impact of diabetes mellitus on prognosis of early breast cancer in Asia.Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis.Lipid profiles within the SABRE trial of anastrozole with and without risedronate.
P2860
Q24194371-A57A0C18-E699-41CB-A9CF-B288A18FD6D7Q26741523-AEE825A8-CFE2-46A5-B40C-E780FB92E994Q26822732-FBF9DA21-11D1-4D8F-A507-0667AED72AB2Q26824762-80955451-F3D1-4AB7-B2C6-3797E458F06CQ26859193-A33CC4AF-7607-40B7-94CF-A91F77A2FFB8Q26859326-92338A13-F681-483B-B516-4066FD615F61Q27008869-6E48BB61-C821-4D78-AD64-6A258D2BAB35Q27024715-293E1CA2-A64E-409C-A529-B0B1C72EC180Q27025860-CDEA19EE-C4AD-4011-8C07-9B7A8AF3AC4AQ28066744-D6967976-AB4B-4D22-AB11-E3E4695EEF71Q28539057-BEA563AF-5D53-4F03-9005-96FDFB970968Q30251498-617A3B25-5081-44A9-99BC-6D851E166020Q30543788-7231B422-16C2-476A-817F-A8D328552355Q31024426-367DE4E5-7D57-4BAC-ABB8-DAE07592E92EQ33441165-F614EB54-B6E1-42E0-A0AE-0F857C70D7C7Q33698446-58492B33-9888-4114-88EF-2B1CA62CFFB2Q33763889-1A9AC2CC-3EA2-493C-B5DE-92AD47831AC4Q33810528-E779D1D4-38B7-4AEE-92DA-6D0CECEAD972Q33895422-B3635316-8AAC-4777-8F01-1DAFF0682CABQ33907581-F1B0550D-8196-41F3-9B4B-731EF77AE9C8Q34004946-DF67D2B4-8042-4B45-B0B9-065514E663F8Q34134780-9E26B2EA-262E-43FC-B51E-33E1DD5406C8Q34230292-1C672497-B9C3-47D4-A07B-6099FA00333EQ34265045-7B001B18-724C-42BC-A4E4-F83F0FF7FCF3Q34347274-88064A9A-448E-411E-AD8C-CA2C00A046C3Q34895561-4682A821-AD64-40C5-BA9C-65BEEF8D4B61Q35023875-DBE2D68D-CDA3-4251-9E3E-BE7DB753DC77Q35054713-664381B8-9F07-4529-ADE7-8016308AF089Q35083481-7E07B441-B21E-44C3-B4C8-EE4C9F4BD592Q35490056-FA7A89D9-1BEB-4A4C-9D07-6804384D9D62Q35607675-266D52CF-4B9E-44D1-9FA7-2B1288F779B0Q35661622-4C39E299-67E2-4066-9A08-D3BE71D3ADF1Q35678104-0140364F-5C12-4E92-9D29-21BC2CF51E0FQ35713616-0B647BE1-D434-4377-9116-D94BDA79C8A7Q35845258-CCE05B08-FA0E-46BE-AF03-4646B809D3B7Q35878669-37603F27-DD4A-4459-BF2B-364EA1212DAEQ35913204-7A6BB2C4-AD34-45DE-948D-8A6B323CEFA3Q36107130-ABA445F6-ED9D-4154-9438-6B32225C8F02Q36140045-F95C5560-D775-4FF5-BD74-063B164B2EADQ36161292-6A1B479E-DB5E-4344-A2B8-FB3CD690E2A1
P2860
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Toxicity of adjuvant endocrine ...... atic review and meta-analysis.
@en
Toxicity of adjuvant endocrine ...... atic review and meta-analysis.
@nl
type
label
Toxicity of adjuvant endocrine ...... atic review and meta-analysis.
@en
Toxicity of adjuvant endocrine ...... atic review and meta-analysis.
@nl
prefLabel
Toxicity of adjuvant endocrine ...... atic review and meta-analysis.
@en
Toxicity of adjuvant endocrine ...... atic review and meta-analysis.
@nl
P2093
P356
P1476
Toxicity of adjuvant endocrine ...... atic review and meta-analysis.
@en
P2093
Bostjan Seruga
Lindsay Carlsson
Saroj Niraula
P304
P356
10.1093/JNCI/DJR242
P407
P577
2011-07-09T00:00:00Z